Data from phase III trial of Sublocade in opioid use disorder published in Journal of Addiction Medicine
Indivior announced the publication of patient-centered outcome endpoints (health status, physical and mental health, medication satisfaction, employment, health insurance status and healthcare resource utilization) of Sublocade (buprenorphine extended-release) injection for subcutaneous use in opioid use disorder by the Journal of Addiction Medicine. These measures were collected during the 24-week, Phase III, randomized, placebo-controlled study assessing the drug's efficacy, safety and tolerability.
The results showed that participants receiving Sublocade versus placebo experienced significant changes from baseline on the EQ-5D-5L index (300/300mg: difference=0.0636) and visual analog scale (300/300mg: difference=5.9, 300/100mg: difference=7.7), and on the SF-36v2 physical component summary score (300/300mg: difference=3.8; 300/100mg: difference=3.2). Treatment satisfaction was significantly higher at the end of study for participants receiving Sublocade 300/300mg and 300/100mg than placebo. Employment increased by 10.8% with Sublocade 300/300mg and 10.0% with 300/100mg but decreased by 12.6% with placebo. Participants receiving Sublocade compared with placebo had significantly fewer hospital days per person-year observed.
See: "Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study." Ling W et al. J Addict Med. March 2019 DOI: http://dx.doi.org/10.1097/ADM.0000000000000517
Related news and insights
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
The Menarini Group and Radius Health announced positive topline results from the phase III EMERALD study evaluating RAD 1901 (elacestrant) as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC).
Gilead Sciences, Inc. announced the FDA approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.